Nigel J Cairns

List of Publications by Citations

367 papers	37,547 citations	94 h-index	188 g-index
402 ext. papers	44,534 ext. citations	7.6 avg, IF	6.53 L-index

#	Paper	IF	Citations
367	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *New England Journal of Medicine*, **2012**, 367, 795-804	59.2	2272
366	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica*, **2012**, 123, 1-11	14.3	1425
365	National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimerls and Dementia*, **2012**, 8, 1-13	1.2	1396
364	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nature Genetics*, **2011**, 43, 436-41	36.3	1367
363	Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *Journal of Neuropathology and Experimental Neurology*, **2012**, 71, 362-81	3.1	1145
362	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
361	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathologica*, **2007** , 114, 5-22	14.3	837
360	Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. *Neuroscience Letters*, **1998**, 251, 205-8	3.3	790
359	Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathologica*, **2014**, 128, 755-66	14.3	776
358	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathologica*, **2010**, 119, 1-4	14.3	711
357	Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. *Annals of Neurology*, **2007**, 61, 427-34	9.4	698
356	The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathologica*, **2016**, 131, 75-86	14.3	524
355	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 18809-14	11.5	519
354	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
353	TDP-43 A315T mutation in familial motor neuron disease. *Annals of Neurology*, **2008**, 63, 535-8	9.4	497
352	TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. *Cell*, **2017**, 170, 649-663.e13	56.2	441
351	Tau and A imaging, CSF measures, and cognition in Alzheimer's disease. *Science Translational Medicine*, **2016**, 8, 338ra66	17.5	418

350	Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. *American Journal of Pathology*, **1998**, 153, 1365-70	5.8	418
349	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. *Lancet Neurology, The*, **2013**, 12, 957-65	24.1	389
348	TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. *American Journal of Pathology*, **2007**, 171, 227-40	5.8	376
347	An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. *Journal of Neurochemistry*, **1997**, 68, 2061-9	6	376
346	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. *Alzheimerls and Dementia*, **2012**, 8, S1-68	1.2	368
345	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nature Genetics*, **2010**, 42, 234-9	36.3	361
344	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature*, **2014** , 505, 550-554	50.4	345
343	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. *Nature Genetics*, **2011**, 44, 200-5	36.3	344
342	The Alzheimer's disease neuroimaging initiative: progress report and future plans. *Alzheimerls and Dementia*, **2010**, 6, 202-11.e7	1.2	332
341	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. *Acta Neuropathologica*, **2009**, 117, 15-8	14.3	325
340	Proteopathic tau seeding predicts tauopathy in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E4376-85	11.5	307
339	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. *Biological Psychiatry*, **2010**, 68, 903-12	7.9	298
338	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. *Alzheimerls and Dementia*, **2013**, 9, e111-94	1.2	296
337	Tissue pH as an indicator of mRNA preservation in human post-mortem brain. *Molecular Brain Research*, **1995**, 28, 311-8		278
336	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. *Acta Neuropathologica*, **2016**, 131, 87-102	14.3	272
335	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. *Journal of Neuropathology and Experimental Neurology*, **2007**, 66, 152-7	3.1	256
334	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4502-9	11.5	253
333	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. *Annals of Neurology*, **2016**, 79, 929-39	9.4	247

332	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Science Translational Medicine*, **2014**, 6, 226ra30	17.5	244
331	TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. *Nature Neuroscience*, **2018**, 21, 228-239	25.5	240
330	Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. *Brain Research*, **2003**, 967, 152-60	3.7	237
329	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. *Nature Genetics*, **1999**, 21, 71-2	36.3	236
328	Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. *Journal of Biological Chemistry*, **2003**, 278, 6521-31	5.4	229
327	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurology, The*, **2018**, 17, 241-250	24.1	224
326	Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99	24.1	207
325	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. *Alzheimerls and Dementia*, **2015**, 11, e1-120	1.2	206
324	Amyloid-□oligomerization in Alzheimer dementia versus high-pathology controls. *Annals of Neurology*, **2013**, 73, 104-19	9.4	195
323	Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. *Journal of Neurochemistry*, **1999**, 73, 1590-7	6	195
322	Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. *Journal of Neuropathology and Experimental Neurology*, **2006**, 65, 571-81	3.1	182
321	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between □Amyloid and Tauopathy. *JAMA Neurology*, **2016**, 73, 1070-7	17.2	179
320	The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. *British Journal of Psychiatry*, **1993**, 162, 385-92	5.4	177
319	A novel Alzheimer disease locus located near the gene encoding tau protein. *Molecular Psychiatry*, **2016**, 21, 108-17	15.1	175
318	HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. *Annals of Neurology*, **2006**, 60, 314-22	9.4	174
317	Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. *NeuroReport*, **2001**, 12, 285-8	1.7	172
316	Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. *Annals of Neurology*, **2010**, 68, 162-72	9.4	168
315	Clinical and neuropathological correlates of depression in Alzheimer's disease. *Psychological Medicine*, **1992**, 22, 877-84	6.9	167

314	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. *Acta Neuropathologica*, **2015**, 129, 469-91	14.3	165
313	Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. *Archives of Neurology*, **2009**, 66, 1557-62		165
312	Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. *Molecular Brain Research*, **2003**, 118, 60-71		161
311	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. *Alzheimerls and Dementia*, **2017**, 13, e1-e85	1.2	157
310	Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 740-7	3.1	154
309	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimerls and Dementia*, **2019**, 15, 106-152	1.2	153
308	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*, **2014**, 23, 6139-46	5.6	152
307	Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. *Annals of Neurology*, **2000**, 48, 868-876	9.4	147
306	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. *Clinical Investigation*, **2012**, 2, 975-984		144
305	Partial volume correction in quantitative amyloid imaging. *NeuroImage*, **2015**, 107, 55-64	7.9	138
304	Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. *British Journal of Psychiatry*, **1994**, 165, 53-9	5.4	138
303	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. *Alzheimerls and Dementia*, **2017**, 13, 561-571	1.2	137
302	Pathologic accumulation of □synuclein and A□in Parkinson disease patients with dementia. *Archives of Neurology*, **2012**, 69, 1326-31		137
301	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. *Alzheimerls and Dementia*, **2015**, 11, 865-84	1.2	132
300	Two-dimensional map of human brain proteins. *Electrophoresis*, **1999**, 20, 907-16	3.6	131
299	Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. *JAMA Neurology*, **2014**, 71, 1394-404	17.2	129
298	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. *Neurology*, **2018**, 91, e1295-e1306	6.5	129
297	Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. *Alzheimerls and Dementia*, **2016**, 12, 882-9	1.2	127

296	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. *Brain*, **2016**, 139, 2249-60	11.2	125
295	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. *Neurology*, **2012**, 79, 221-8	6.5	124
294	The cytoskeleton in neurodegenerative diseases. *Journal of Pathology*, **2004**, 204, 438-49	9.4	123
293	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 64-74	24.1	121
292	Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiology of Aging*, **2016**, 41, 200.e13-200.e20	5.6	119
291	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nature Communications*, **2020**, 11, 2612	17.4	118
290	Amyloid imaging of Lewy body-associated disorders. *Movement Disorders*, **2010**, 25, 2516-23	7	118
289	Distinct pathological subtypes of FTLD-FUS. *Acta Neuropathologica*, **2011**, 121, 207-18	14.3	116
288	Pick's disease is associated with mutations in the tau gene. *Annals of Neurology*, **2000**, 48, 859-867	9.4	116
287	Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. *Human Mutation*, **2004**, 23, 358-67	4.7	114
286	Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. *Electrophoresis*, **1999**, 20, 928-34	3.6	114
285	Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. *Annals of Neurology*, **2011**, 70, 274-85	9.4	113
284	Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease and Down syndrome. *Electrophoresis*, **2001**, 22, 172-9	3.6	111
283	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. *Acta Neuropathologica Communications*, **2013**, 1, 65	7.3	110
282	TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. *Acta Neuropathologica*, **2009**, 118, 633-45	14.3	110
281	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. *Acta Neuropathologica*, **2015**, 129, 757-62	14.3	109
280	The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. *Life Sciences*, **2001**, 68, 2741-50	6.8	107
279	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. *Alzheimerls and Dementia*, **2017**, 13, 727-738	1.2	106

278	alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. *American Journal of Pathology*, **2004**, 164, 2153-61	5.8	106
277	Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. *Annals of Clinical and Translational Neurology*, **2015**, 2, 949-59	5.3	102
276	The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. *Brain*, **1999**, 122 (Pt 9), 1709-19	11.2	99
275	Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. *Acta Neuropathologica*, **2015**, 129, 39-52	14.3	98
274	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. *Acta Neuropathologica*, **2014**, 127, 407-18	14.3	97
273	Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. *Neuroscience Letters*, **1997**, 230, 49-52	3.3	94
272	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. *Archives of Neurology*, **2011**, 68, 488-97		93
271	Haplotypes extending across ACE are associated with Alzheimer's disease. *Human Molecular Genetics*, **2003**, 12, 859-67	5.6	93
270	Overlap between neurodegenerative disorders. *Neuropathology*, **2005**, 25, 111-24	2	90
269	Parkinson's disease and multiple system atrophy have distinct □synuclein seed characteristics. *Journal of Biological Chemistry*, **2019**, 294, 1045-1058	5.4	89
268	Decreased brain levels of 2',3'-cyclic nucleotide-3'-phosphodiesterase in Down syndrome and Alzheimer's disease. *Neurobiology of Aging*, **2001**, 22, 547-53	5.6	88
267	Decreased phospholipase A2 activity in Alzheimer brains. *Biological Psychiatry*, **1995**, 37, 13-7	7.9	88
266	Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. *Journal of Neurochemistry*, **1994**, 62, 1062-6	6	86
265	Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. *Scientific Reports*, **2017**, 7, 9520	4.9	84
264	Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. *Nature Genetics*, **1999**, 22, 16-7; author reply 21-2	36.3	84
263	VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death. *Journal of Biological Chemistry*, **2009**, 284, 12384-98	5.4	83
262	Overexpressed protein disulfide isomerase in brains of patients with sporadic Creutzfeldt-Jakob disease. *Neuroscience Letters*, **2002**, 334, 196-200	3.3	83
261	Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. *Biochemical and Biophysical Research Communications*, **2001**, 281, 84-93	3.4	82

260	Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease. *Neuroscience Letters*, **1995**, 200, 57-60	3.3	82
259	Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex. *British Journal of Psychiatry*, **2000**, 176, 236-42	5.4	81
258	Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. *Biochemical and Biophysical Research Communications*, **1997**, 240, 84-7	3.4	79
257	C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. *JAMA Neurology*, **2013**, 70, 736-41	17.2	77
256	Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. *Naunyn-Schmiedebergls Archives of Pharmacology*, **2001**, 363, 139-45	3.4	77
255	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. *NeuroImage*, **2017**, 161, 171-178	7.9	76
254	Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. *Neuroscience Letters*, **2003**, 341, 177-80	3.3	76
253	Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. *Neuroscience Letters*, **2001**, 303, 79-82	3.3	76
252	Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. *Scientific Reports*, **2016**, 6, 38187	4.9	76
251	Widespread tau seeding activity at early Braak stages. *Acta Neuropathologica*, **2017**, 133, 91-100	14.3	75
250	The structural basis for optimal performance of oligothiophene-based fluorescent amyloid ligands: conformational flexibility is essential for spectral assignment of a diversity of protein aggregates. *Chemistry - A European Journal*, **2013**, 19, 10179-92	4.8	73
249	The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR. *Molecular Brain Research*, **2002**, 106, 101-16		73
248	Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. *Annals of Neurology*, **2017**, 81, 549-559	9.4	71
247	TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. *Neuroscience Letters*, **2018**, 678, 8-15	3.3	71
246	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. *Brain*, **2019**, 142, 1063-1076	11.2	71
245	A presenilin-1 truncating mutation is present in two cases with autopsy-confirmed early-onset Alzheimer disease. *American Journal of Human Genetics*, **1998**, 62, 70-6	11	70
244	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. *Acta Neuropathologica*, **2012**, 124, 373-82	14.3	69
243	Enrichment of human brain proteins by heparin chromatography. *Electrophoresis*, **1999**, 20, 2970-6	3.6	69

242	Functional connectivity in autosomal dominant and late-onset Alzheimer disease. *JAMA Neurology*, **2014**, 71, 1111-22	17.2	68
241	[3H](-)nicotine binding sites in fetal human brain. *Brain Research*, **1988**, 475, 1-7	3.7	68
240	Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. *Neuroscience Letters*, **1996**, 212, 111-4	3.3	66
239	Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome. *Neuroscience Letters*, **1999**, 260, 9-12	3.3	65
238	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). *Lancet Neurology, The*, **2016**, 15, 1317-1325	24.1	64
237	Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer's disease: an early event in disease pathogenesis. *Journal of Neurochemistry*, **2013**, 127, 733-8	6	63
236	Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. *Alzheimerls and Dementia*, **2016**, 12, 164-169	1.2	62
235	Similar deficits of central histaminergic system in patients with Down syndrome and Alzheimer disease. *Neuroscience Letters*, **1997**, 222, 183-6	3.3	61
234	Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. *Human Mutation*, **2008**, 29, 512-21	4.7	61
233	Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. *BMC Neurology*, **2006**, 6, 44	3.1	61
232	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60
231	Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. *Science Translational Medicine*, **2017**, 9,	17.5	58
230	The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. *Neurology*, **2013**, 81, 1425-33	6.5	56
229	Clinical and psychometric distinction of frontotemporal and Alzheimer dementias. *Archives of Neurology*, **2007**, 64, 535-40		55
228	Tumour necrosis factor-alpha gene polymorphisms and Alzheimer's disease. *Neuroscience Letters*, **2003**, 350, 61-5	3.3	55
227	Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. *Journal of Investigative Medicine*, **2001**, 49, 41-6	2.9	55
226	The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 717-726	3.1	55
225	Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease. *Neuroscience Letters*, **1996**, 214, 33-6	3.3	54

224	Pathological correlates of white matter hyperintensities on magnetic resonance imaging. *Dementia and Geriatric Cognitive Disorders*, **2015**, 39, 92-104	2.6	52
223	Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. *Current Neurology and Neuroscience Reports*, **2014**, 14, 499	6.6	52
222	Evidence against increased oxidative DNA-damage in Down syndrome. *Neuroscience Letters*, **1997**, 235, 137-40	3.3	52
221	Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. *PLoS ONE*, **2012**, 7, e49483	3.7	52
220	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. *Neurobiology of Disease*, **2019**, 121, 327-337	7.5	52
219	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. *Neurology*, **2014**, 83, 434-40	6.5	51
218	Aberrant expression of bcl-2 gene family in Down's syndrome brains. *Molecular Brain Research*, **1997**, 48, 53-9		51
217	Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease. *Molecular Brain Research*, **2003**, 116, 155-8		51
216	The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. *NeuroReport*, **2001**, 12, 631-4	1.7	51
215	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. *Acta Neuropathologica*, **2019**, 137, 879-899	14.3	50
214	Clinical Features of Alzheimer Disease With and Without Lewy Bodies. *JAMA Neurology*, **2015**, 72, 789-96	17.2	50
213	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiology of Aging*, **2016**, 38, 214.e7-214.e10	5.6	49
212	TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. *Journal of Neuropathology and Experimental Neurology*, **2008**, 67, 271-9	3.1	49
211	Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). *Neuropathology*, **2015**, 35, 390-400	2	47
210	Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. *Journal of Neural Transmission*, **2010**, 117, 227-39	4.3	47
209	Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. *Proteomics - Clinical Applications*, **2007**, 1, 1373-84	3.1	47
208	Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. *Alzheimer Disease and Associated Disorders*, **2007**, 21, 1-7	2.5	47
207	Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. *Neuroscience Letters*, **2001**, 300, 41-4	3.3	47

206	NMR spectroscopy of human post mortem cerebrospinal fluid: distinction of Alzheimer's disease from control using pattern recognition and statistics. *NMR in Biomedicine*, **1993**, 6, 163-7	4.4	47
205	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. *Brain*, **2018**, 141, 1486-1500	11.2	46
204	Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. *Alzheimerls and Dementia*, **2013**, 9, 176-88	1.2	45
203	An optimistic view for quantifying mRNA in post-mortem human brain. *Molecular Brain Research*, **2003**, 116, 7-16		45
202	Human brain nucleoside diphosphate kinase activity is decreased in Alzheimer's disease and Down syndrome. *Biochemical and Biophysical Research Communications*, **2002**, 296, 970-5	3.4	44
201	The levels of water-soluble and triton-soluble A□are increased in Alzheimer's disease brain. *Brain Research*, **2012**, 1450, 138-47	3.7	43
200	What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?. *Neuropathology*, **2008**, 28, 351-65	2	43
199	The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). *Alzheimerls and Dementia*, **2013**, 9, 189-98	1.2	42
198	Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. *Neurobiology of Aging*, **2005**, 26, 795-802	5.6	42
197	Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease. *Life Sciences*, **1996**, 59, 537-44	6.8	42
196	Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease. *British Journal of Psychiatry*, **1993**, 163, 364-8	5.4	42
195	Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. *Journal of Neural Transmission*, **2008**, 115, 1661-71	4.3	41
194	alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. *Acta Neuropathologica*, **2004**, 108, 213-23	14.3	41
193	Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late-onset sporadic Alzheimer's disease. *Psychiatry and Clinical Neurosciences*, **2000**, 54, 523-9	6.2	41
192	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 396-406	17.2	41
191	Differential expression of molecular chaperones in brain of patients with Down syndrome. *Electrophoresis*, **2001**, 22, 1233-41	3.6	39
190	In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. *NeuroImage*, **2017**, 148, 296-304	7.9	37
189	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. *Neurology*, **2013**, 80, 2121-9	6.5	37

188	Polyamines in frontal cortex of patients with Down syndrome and Alzheimer disease. *Neuroscience Letters*, **1996**, 206, 193-5	3.3	37
187	Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. *Human Molecular Genetics*, **2008**, 17, 759-67	5.6	35
186	Amyloid precursor protein mRNA levels in Alzheimer's disease brain. *Molecular Brain Research*, **2004** , 122, 1-9		35
185	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. *PLoS ONE*, **2018**, 13, e0195838	3.7	34
184	A quantitative study of □synuclein pathology in fifteen cases of dementia associated with Parkinson disease. *Journal of Neural Transmission*, **2014**, 121, 171-81	4.3	34
183	Shortfalls in the peptidyl-prolyl cis-trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias. *Neurobiology of Disease*, **2004**, 17, 237-49	7.5	34
182	Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. *Neuroscience Letters*, **2004**, 358, 142-6	3.3	34
181	Expression of DNA excision-repair-cross-complementing proteins p80 and p89 in brain of patients with Down Syndrome and Alzheimer's disease. *Neuroscience Letters*, **1998**, 251, 45-8	3.3	33
180	Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. *Human Genetics*, **2004**, 114, 478-83	6.3	33
179	Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2005**, 132B, 5-8	3.5	33
178	Apolipoprotein E epsilon4 allele has no effect on age at onset or duration of disease in cases of frontotemporal dementia with pick- or microvacuolar-type histology. *Experimental Neurology*, **2000**, 163, 452-6	5.7	33
177	Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome. *Neuroscience Letters*, **1999**, 260, 141-5	3.3	33
176	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. *Alzheimerls and Dementia*, **2017**, 13, 1197-1206	1.2	32
175	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. *Molecular Neurodegeneration*, **2019**, 14, 18	19	32
174	Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases. *Neurology*, **2013**, 81, 520-7	6.5	32
173	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurology*, **2021**, 78, 102-113	17.2	32
172	The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 210-219	3.1	32
171	Rarity of the Alzheimer disease-protective APP A673T variant in the United States. *JAMA Neurology* , **2015**, 72, 209-16	17.2	31

170	Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val-->Ile) mutation cases: a morphometric investigation. *Journal of the Neurological Sciences*, **1997**, 149, 177-84	3.2	31
169	What does the study of the spatial patterns of pathological lesions tell us about the pathogenesis of neurodegenerative disorders?. *Neuropathology*, **2001**, 21, 1-12	2	31
168	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. *Nature Genetics*, **2021**, 53, 294-303	36.3	31
167	Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43. *Journal of Molecular Neuroscience*, **2011**, 45, 402-8	3.3	30
166	Presenilin-1 intron 8 polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. *Neuroscience Letters*, **1997**, 222, 68-9	3.3	30
165	What does the study of the spatial patterns of pathological lesions tell us about the pathogenesis of neurodegenerative disorders?. *Neuropathology*, **2001**, 21, 1-12	2	30
164	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. *Neurobiology of Aging*, **2009**, 30, 656-65	5.6	29
163	Olfactory bulb in multiple system atrophy. *Movement Disorders*, **2003**, 18, 938-42	7	29
162	Beta A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease. *Neuroscience Letters*, **1993**, 149, 137-40	3.3	29
161	TDP-43 expression influences amyloid plaque deposition and tau aggregation. *Neurobiology of Disease*, **2017**, 103, 154-162	7.5	28
160	A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. *Stem Cell Reports*, **2019**, 13, 939-955	8	28
159	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. *Journal of Biological Chemistry*, **2016**, 291, 27204-27218	5.4	27
158	Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (A) in Alzheimer's Disease. *Scientific Reports*, **2016**, 6, 35636	4.9	27
157	Apolipoprotein E e4 allele frequency in patients with multiple system atrophy. *Neuroscience Letters*, **1997**, 221, 161-4	3.3	27
156	Decreased transcription factor junD in brains of patients with Down syndrome. *Neuroscience Letters* , **1998**, 252, 159-62	3.3	27
155	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. *Genome Medicine*, **2018**, 10, 43	14.4	26
154	Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease. *Neuroscience Letters*, **2005**, 374, 124-8	3.3	26
153	Evidence for apoptosis in the fetal Down syndrome brain. *Journal of Child Neurology*, **2001**, 16, 438-42	2.5	26

152	Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP. *Translational Psychiatry*, **2018**, 8, 265	8.6	26
151	Widespread distribution of tauopathy in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2018**, 72, 177-185	5.6	26
150	Interaction of neuritic plaques and education predicts dementia. *Alzheimer Disease and Associated Disorders*, **2008**, 22, 188-93	2.5	25
149	Molecular analysis of the presenilin 1 (S182) gene in "sporadic" cases of Alzheimer's disease: identification and characterisation of unusual splice variants. *Journal of Neurochemistry*, **1996**, 66, 1774-7	6	25
148	Neuronal intranuclear inclusions are ultrastructurally and immunologically distinct from cytoplasmic inclusions of neuronal intermediate filament inclusion disease. *Acta Neuropathologica*, **2005**, 110, 360-8	14.3	25
147	Expression of cellular prion protein in the frontal and occipital lobe in Alzheimer's disease, diffuse Lewy body disease, and in normal brain: an immunohistochemical study. *Journal of Histochemistry and Cytochemistry*, **2005**, 53, 929-40	3.4	25
146	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*, **2018**, 141, 2895-2907	11.2	25
145	A quantitative study of the pathological changes in white matter in multiple system atrophy. *Neuropathology*, **2007**, 27, 221-7	2	24
144	Neuroendocrine-specific protein C, a marker of neuronal differentiation, is reduced in brain of patients with Down syndrome and Alzheimer's disease. *Biochemical and Biophysical Research Communications*, **2000**, 276, 329-34	3.4	24
143	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. *Neurology*, **2017**, 88, 1273-1281	6.5	23
142	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. *Alzheimerls and Dementia*, **2015**, 11, 815-22	1.2	23
141	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. *Neurology*, **2015**, 85, 790-8	6.5	23
140	Spatial patterns of the tau pathology in progressive supranuclear palsy. *Neurological Sciences*, **2013**, 34, 337-44	3.5	23
139	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. *Alzheimerls and Dementia*, **2010**, 6, 274-9	1.2	23
138	Endogenous opioids in frontal cortex of patients with Down syndrome. *Neuroscience Letters*, **1996**, 203, 111-4	3.3	23
137	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. *Brain*, **2019**, 142, 1429-1440	11.2	22
136	Mutation analysis of patients with neuronal intermediate filament inclusion disease (NIFID). *Neurobiology of Aging*, **2006**, 27, 778.e1-778.e6	5.6	22
135	Spatial patterns of alpha-synuclein positive glial cytoplasmic inclusions in multiple system atrophy. *Movement Disorders*, **2004**, 19, 109-12	7	22

134	No evidence for an association between Saitohin Q7R polymorphism and Alzheimer's disease. *Annals of Neurology*, **2002**, 52, 690-1	9.4	22
133	Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease. *Neuroscience Letters*, **1999**, 273, 61-83	3.3	22
132	FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy. *Journal of Molecular Neuroscience*, **2011**, 45, 409-21	3.3	21
131	In vivo [F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. *Neurology*, **2018**, 90, e896-e906	6.5	20
130	The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease. *Acta Neuropathologica*, **2011**, 121, 219-28	14.3	20
129	Evidence for the relation of herpes simplex virus type 1 to Down syndrome and Alzheimer's disease. *Electrophoresis*, **2001**, 22, 445-8	3.6	20
128	Decreased cyclin dependent kinase in brain of patients with Down syndrome. *Neuroscience Letters*, **1996**, 216, 68-70	3.3	20
127	Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease. *Alzheimerls and Dementia*, **2017**, 13, 613-623	1.2	19
126	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. *Journal of Neuropathology and Experimental Neurology*, **2015**, 74, 1086-92	3.1	19
125	Synthesis of Thiophene-Based Optical Ligands That Selectively Detect Tau Pathology in Alzheimer's Disease. *Chemistry - A European Journal*, **2017**, 23, 17127-17135	4.8	19
124	Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration?. *Neuropathology*, **2002**, 22, 133-46	2	19
123	Increased steady state mRNA levels of DNA-repair genes XRCC1, ERCC2 and ERCC3 in brain of patients with Down syndrome. *Life Sciences*, **1999**, 64, 1689-99	6.8	19
122	Brain vasopressin levels in Down syndrome and Alzheimer's disease. *Brain Research*, **1998**, 806, 55-9	3.7	18
121	Thyroid stimulating hormone-receptor overexpression in brain of patients with Down syndrome and Alzheimer's disease. *Life Sciences*, **1999**, 64, 1037-44	6.8	18
120	Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disorders. *Journal of Neural Transmission*, **2012**, 119, 1551-60	4.3	17
119	Distinguishable effects of presenilin-1 and APP717 mutations on amyloid plaque deposition. *Neurobiology of Aging*, **2001**, 22, 367-76	5.6	17
118	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101767	5.3	16
117	Glyceraldehyde 3-phosphate dehydrogenase and endothelin-1 immunoreactivity is associated with cerebral white matter damage in dentatorubral-pallidoluysian atrophy. *Neuropathology*, **2003**, 23, 36-43	2	16

116	Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. *Neuropathology*, **2001**, 21, 266-71	2	16
115	Human brain cytosolic histamine-N-methyltransferase is decreased in Down syndrome and increased in Pick's disease. *Neuroscience Letters*, **2002**, 321, 169-72	3.3	16
114	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. *Molecular Neurodegeneration*, **2020**, 15, 57	19	16
113	Heritability and genetic variance of dementia with Lewy bodies. *Neurobiology of Disease*, **2019**, 127, 492-501	7.9	15
112	Amyloid-β Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracer and Exhibit Nanoscale Heterogeneity. *Frontiers in Neurology*, **2018**, 9, 169	4.1	15
111	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. *Acta Neuropathologica Communications*, **2020**, 8, 5	7.3	15
110	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. *Brain Communications*, **2020**, 2, fcaa025	4.5	14
109	Spinal cord mGlu1a receptors: possible target for amyotrophic lateral sclerosis therapy. *Pharmacology Biochemistry and Behavior*, **2002**, 73, 447-54	3.9	14
108	Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes. *American Journal of Medical Genetics Part A*, **2001**, 105, 761-4		14
107	Parkinson disease clinical subtypes: key features & clinical milestones. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1272-1283	5.3	13
106	Evidence against increased glycoxidation in patients with Alzheimer's disease. *Neuroscience Letters*, **1997**, 232, 49-52	3.3	13
105	Amyotrophic lateral sclerosis and non-tau frontotemporal lobar degeneration. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2017**, 145, 369-381	3	13
104	Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. *Alzheimer Disease and Associated Disorders*, **2017**, 31, 232-238	2.5	12
103	FUS: A new actor on the frontotemporal lobar degeneration stage. *Neurology*, **2010**, 74, 354-6	6.5	12
102	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. *JAMA Neurology*, **2016**, 73, 1125-32	17.2	12
101	Clinically early-stage CSF3 mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. *Acta Neuropathologica Communications*, **2015**, 3, 73	7.3	11
100	Comparative quantitative study of 'signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders. *Journal of Neural Transmission*, **2015**, 122, 1355-67	4.3	11
99	Spatial pattern of prion protein deposits in patients with sporadic Creutzfeldt-Jakob disease. *Neuropathology*, **2001**, 21, 19-24	2	11

98	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. *Journal of Neuropathology and Experimental Neurology*, **2021**, 80, 102-111	3.1	11
97	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. *Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 669-677	5.2	11
96	Characterization of a brain permeant fluorescent molecule and visualization of A parenchymal plaques, using real-time multiphoton imaging in transgenic mice. *Organic Letters*, **2014**, 16, 3640-3	6.2	10
95	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiology of Aging*, **2017**, 49, 214.e13-214.e15	5.6	10
94	Spatial topography of the neurofibrillary tangles in cortical and subcortical regions in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2007**, 13, 50-4	3.6	10
93	Aberrant accentuation of neurofibrillary degeneration in the hippocampus of Alzheimer's disease with amyloid precursor protein 717 and presenilin-1 gene mutations. *Journal of the Neurological Sciences*, **2005**, 234, 55-65	3.2	10
92	Spatial pattern of prion protein deposits in patients with sporadic Creutzfeldt Jakob disease. *Neuropathology*, **2001**, 21, 19-24	2	10
91	The spatial patterns of Pick bodies, Pick cells and Alzheimer's disease pathology in Pick's disease. *Neuropathology*, **1999**, 19, 64-70	2	10
90	A comprehensive screening of copy number variability in dementia with Lewy bodies. *Neurobiology of Aging*, **2019**, 75, 223.e1-223.e10	5.6	10
89	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. *Movement Disorders*, **2021**, 36, 948-954	7	10
88	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. *Annals of Neurology*, **2018**, 84, 741-753	9.4	10
87	Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology. *Neurological Sciences*, **2009**, 30, 471-7	3.5	9
86	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. *Nature Communications*, **2021**, 12, 3825	17.4	9
85	Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls. *PLoS ONE*, **2018**, 13, e0200251	3.7	8
84	Deficient brain snRNP70K in patients with Down syndrome. *Electrophoresis*, **2001**, 22, 43-8	3.6	8
83	Increased phosphoglycerate kinase in the brains of patients with Down syndrome but not with Alzheimer disease. *Clinical Science*, **1999**, 96, 279	6.5	8
82	Increased phosphoglycerate kinase in the brains of patients with Down's syndrome but not with Alzheimer's disease. *Clinical Science*, **1999**, 96, 279-285	6.5	8
81	Comparing amyloid plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. *Acta Neuropathologica*, **2021**, 142, 689-706	14.3	8

80	Cortical degeneration in chronic traumatic encephalopathy and Alzheimer's disease neuropathologic change. *Neurological Sciences*, **2019**, 40, 529-533	3.5	8
79	Whipple's disease masquerades as dementia with Lewy bodies. *Alzheimer Disease and Associated Disorders*, **2015**, 29, 85-89	2.5	7
78	Pathology of the Superior Colliculus in Chronic Traumatic Encephalopathy. *Optometry and Vision Science*, **2017**, 94, 33-42	2.1	7
77	Pick's disease is associated with mutations in the tau gene **2000**, 48, 859		7
76	The Utility of the National Alzheimer's Coordinating Center's Database for the Rapid Assessment of Evolving Neuropathologic Conditions. *Alzheimer Disease and Associated Disorders*, **2020**, 34, 105-111	2.5	6
75	Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy. *Journal of Neural Transmission*, **2017**, 124, 185-192	4.3	6
74	Neurons and extracellular neurofibrillary tangles in the hippocampal subdivisions in early-onset familial Alzheimer's disease: a case study. *Psychiatry and Clinical Neurosciences*, **1997**, 51, 227-31	6.2	6
73	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. *Nature Communications*, **2021**, 12, 5346	17.4	6
72	Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID). *Journal of Neural Transmission*, **2011**, 118, 1651-7	4.3	5
71	A quantitative study of the pathological changes in cortical neurons in sporadic Creutzfeldt-Jakob disease. *Neuropathology*, **2003**, 23, 181-7	2	5
70	A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation. *Histology and Histopathology*, **2011**, 26, 185-90	1.4	5
69	Spatial patterns of the pathological changes in the cerebellar cortex in sporadic Creutzfeldt-Jakob disease (sCJD). *Folia Neuropathologica*, **2003**, 41, 183-9	2.6	5
68	Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2020**, 7, 2475-2480	5.3	4
67	Gigaxonin mutation analysis in patients with NIFID. *Neurobiology of Aging*, **2011**, 32, 1528-9	5.6	4
66	Variably Protease-sensitive Prionopathy in an Apparent Cognitively Normal 93-Year-Old. *Alzheimer Disease and Associated Disorders*, **2015**, 29, 173-6	2.5	4
65	Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument. *Alzheimer Disease and Associated Disorders*, **2020**, 34, 112-117	2.5	4
64	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. *Acta Neuropathologica Communications*, **2020**, 8, 196	7.3	4
63	Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down Syndrome and Alzheimer's disease **1999**, 20, 928		4

62	Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). *Neurological Sciences*, **2011**, 32, 653-9	3.5	3
61	Neurons and neurofibrillary tangles in the hippocampal cortex in familial and sporadic Alzheimer's disease. *Neuropathology*, **1997**, 17, 301-306	2	3
60	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. *Biological Psychiatry*, **2021**, 89, 825-835	7.9	3
59	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. *Translational Psychiatry*, **2021**, 11, 483	8.6	3
58	Neuronal intermediate filament inclusion disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2008**, 89, 443-8	3	2
57	Prion-like □synuclein pathology in the brain of infants with Krabbe disease.. *Brain*, **2022**,	11.2	2
56	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration209-248		2
55	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. *Nature Communications*, **2021**, 12, 7065	17.4	2
54	Genome-wide association study and functional validation implicates JADE1 in tauopathy. *Acta Neuropathologica*, **2021**, 1	14.3	2
53	Purkinje cell loss and astrocytosis in the cerebellum in familial and sporadic Alzheimer's disease **1996**, 214, 33-33		2
52	IC-01-03: Classifying TAU Pet Positivity With [18F]-AV-1451 in Preclinical Alzheimer's Disease **2016**, 12, P2-P3		2
51	O5-01-06: TAU Pet Imaging with AV-1451 in Autosomal Dominant Alzheimer's Disease: Update from the Dominantly Inherited Alzheimer Network (DIAN) **2016**, 12, P378-P378		2
50	O2-06-01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study **2012**, 8, P244-P245		1
49	Neuroanatomy and Neuropathology **2005**, 21-55		1
48	Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways. *Brain Communications*, **2020**, 2, fcaa167	4.5	1
47	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure		1
46	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. *Scientific Reports*, **2020**, 10, 12184	4.9	1
45	O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer□ Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) **2016**, 12, P226-P226		1

44	O4-11-01: TDP-43 EXPRESSION IN AN APP/PS1 BACKGROUND REDUCES PLAQUE DEPOSITION AND REGULATES CALCINEURIN EXPRESSION **2016**, 12, P360-P360		1
43	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90.. *Scientific Reports*, **2022**, 12, 6117	4.9	1
42	Neuronal Intermediate Filament Inclusion Disease404-411		0
41	Tauopathy in autosomal dominant and late-onset Alzheimer disease. *Alzheimerls and Dementia*, **2020**, 16, e041683	1.2	
40	IC-P-179: TAU Imaging Relationships With Amyloid B Imaging, CSF TAU/AB42, and Cognition in Alzheimer's Disease **2016**, 12, P130-P131		
39	IC-P-138: POSTERIOR CEREBRAL ATROPHY ASSOCIATED WITH THE PSEN1 I229F MUTATION **2014**, 10, P78-P79		
38	P4-146: POSTERIOR CEREBRAL ATROPHY ASSOCIATED WITH THE PSEN1 I229F MUTATION **2014**, 10, P842-P842		
37	[IC-P-057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P47-P47		
36	[P3□63]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER's DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE **2017**, 13, P1043-P1044		
35	[P2□72]: UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P768-P769		
34	[P2□36]: HIPPOCAMPAL SCLEROSIS AND COMORBIDITIES IN THE AGING BRAIN **2017**, 13, P803-P803		
33	[P4□57]: FUNCTIONAL CHANGES IN MEMORY ASSOCIATED WITH TDP-43 EXPRESSION IN AN APP/PSEN1 MOUSE MODEL **2017**, 13, P1279-P1280		
32	[IC-P-054]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK **2017**, 13, P44-P45		
31	[IC-P-166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY **2017**, 13, P125-P126		
30	[O1□02□3]: EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK **2017**, 13, P186		
29	[S3□01□2]: NEUROPATHOLOGIC HETEROGENEITY IN FAMILIAL AND LATE-ONSET ALZHEIMER'S DISEASE **2017**, 13, P877		
28	[O1□02□4]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY **2017**, 13, P186-P187		
27	P2-108: Differentiating corticobasal degeneration and Alzheimer disease by longitudinal clinical and cognitive features **2015**, 11, P525-P525		

26	P1-206: Clinical features of Alzheimer disease with and without lewy bodies **2015**, 11, P428-P429	
25	O4-02-01: Age-related neuropathology helps distinguish autosomal dominant from late-onset Alzheimer disease **2015**, 11, P269-P269	
24	O2-07-01: Neuropathology of preclinical and incipient Alzheimer's dementia **2011**, 7, S303-S303	
23	The Challenge and Public Health Implications of Alzheimer Overdiagnosis in the Oldest Old□Reply. *Archives of Neurology*, **2010**, 67, 899	
22	Letter to the editor. *Journal of Neuropathology and Experimental Neurology*, **2006**, 65, 97; author reply 97-8	3.1
21	Spatial patterns of the pathological changes in the temporal lobe of patients with neuronal intermediate filament inclusion disease. *Neuropathology*, **2005**, 25, 298-303	2
20	Two-dimensional map of human brain proteins327-336	
19	Unravelling the mysteries of frontotemporal dementia. *Missouri Medicine*, **2013**, 110, 411-6	0.8
18	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. *FASEB Journal*, **2007**, 21, A25	0.9
17	An alternative in vitro model of neurodegeneration in FTLD-U with PGRN mutation. *FASEB Journal*, **2008**, 22, 58.7	0.9
16	P1-254: Principal Component Analysis of [18F]-Av-1451 TAU Pet in Alzheimer□ Disease and Frontotemporal Dementia **2016**, 12, P507-P508	
15	P1-116: Classifying TAU Pet Positivity with [18F]-AV-1451 in Preclinical Alzheimer's Disease **2016**, 12, P446-P447	
14	P3-089: Influence of Parkinson□ Disease Candidate Genes On Lewy Body Pathology in Autopsy-Confirmed Alzheimer's Disease Cases **2016**, 12, P854-P854	
13	P3-234: Similarities and Differences in Patterns of [F18]-AV-1451 and [F18]-FDG in Frontotemporal Dementia **2016**, 12, P915-P916	
12	IC-P-204: Principal Component Analysis of [18F]-Av-1451 TAU PET in Alzheimer□ Disease and Frontotemporal Dementia **2016**, 12, P145-P146	
11	IC-P-206: Similarities and Differences in Patterns of [F18]-Av-1451 And [F18]-FDG in Frontotemporal Dementia **2016**, 12, P147-P147	
10	O3-04-03: Age-Related Neuropathology Helps Distinguish Autosomal Dominant from Late-Onset Alzheimer's Disease **2016**, 12, P291-P292	
9	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network **2016**, 12, P378-P379	

8 P1-099: Purification and Quantitative Characterization of Amyloid-Beta Oligomers from Alzheimer's Disease Brain Lysates **2016**, 12, P439-P439

7 P1-100: Amyloid-Beta (Aβ) Isoforms and Ptms of Soluble Aβ Oligomers from Human Brain **2016**, 12, P439-P440

6 IC-P-046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY **2019**, 15, P48-P49

5 IC-P-195: QUANTIFICATION OF WHITE MATTER CELLULARITY IN PRECLINICAL AND EARLY SYMPTOMATIC ALZHEIMER DISEASE USING NEURO-IMMNUE IMAGING **2018**, 14, P161-P162

4 IC-P-062: EVALUATING NEURO-IMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTEM HUMAN BRAIN **2018**, 14, P57-P58

3 IC-02-01: THE RELATIONSHIP BETWEEN TAU PET AND AGE ACROSS THE LIFESPAN **2018**, 14, P1-P2

2 Hippocampal neurobiology and function in an aged mouse model of TDP-43 proteinopathy in an APP/PSEN1 background. *Neuroscience Letters*, **2021**, 758, 136010 3·3

1 Molecular classification of frontotemporal lobar degeneration (FTLD) with genetic correlations299-299